PD-1/PD-L1信号通路在不同组织来源间充质干细胞中免疫调节作用的研究进展

孔伟浩; 张剑

doi:10.3969/j.issn.1674-7445.2017.06.015

PD-1/PD-L1信号通路在不同组织来源间充质干细胞中免疫调节作用的研究进展

doi: 10.3969/j.issn.1674-7445.2017.06.015

孔伟浩,
张剑^,

510630 广州，中山大学附属第三医院肝脏外科暨肝移植中心

基金项目:

广州市科学研究专项项目 201707010112

详细信息

通讯作者:
张剑, Email: zhangjian629@sina.com

中图分类号: R392.4, R617
计量
- 文章访问数: 149
- HTML全文浏览量: 106
- PDF下载量: 16
- 被引次数: 0
出版历程
- 收稿日期: 2017-08-21
- 网络出版日期: 2021-01-19
- 刊出日期: 2017-11-15

摘要

摘要: 间充质干细胞（MSCs）是一类具有自我更新、多向分化、免疫调节功能的干细胞，能够从骨髓、脂肪、脐血等组织中分离得到。程序性死亡分子1（PD-1）/程序性死亡分子1配体（PD-L1）信号通路在免疫反应的负性调控和维持外周免疫耐受中发挥着重要作用。近年来，PD-1/PD-L1信号通路在MSCs中的作用逐渐受到重视。本文就PD-1/PD-L1通路在不同组织来源MSCs中免疫调节作用的研究现状进行综述。
- 程序性死亡分子1（PD-1） /
- 程序性死亡分子1配体（PD-L1） /
- 间充质干细胞 /
- 调节性T细胞 /
- 免疫调节 /
- 小干扰核糖核酸（siRNA） /
- 吲哚胺-2，3双加氧酶（IDO） /
- 白细胞介素

HTML全文

参考文献(23)

[1]	李猛, 盛宏霞, 张斌, 等. 脐血来源造血干细胞体外培养扩增技术研究进展[J/CD]. 中华细胞与干细胞杂志(电子版), 2016, 6(2): 127-133. DOI: 10.3877/cma.j.issn.2095-1221.2016.02.010. Li M, Sheng HX, Zhang B, et al. Study progress of ex vivo expansion of human cord blood hematopoietic stem cell[J/CD]. Chin J Cell Stem Cell(Electr Edit), 2016, 6(2): 127-133. DOI: 10.3877/cma.j.issn.2095-1221.2016.02.010.
[2]	马锡慧, 肖漓, 石炳毅, 等. 间充质干细胞免疫抑制作用及其在移植免疫中应用的研究进展[J/CD]. 中华细胞与干细胞杂志(电子版), 2015, 5(1): 42-47. DOI: 10.3877/cma.j.issn.2095-1221.2015.01.009. Ma XH, Xiao L, Shi BY, et al. Research advance in immunosuppressive action and application of mesenchymal stem cells in transplantation immunity[J/CD]. Chin J Cell Stem Cell(Electr Edit), 2015, 5(1): 42-47.DOI: 10.3877/cma.j.issn.2095-1221.2015.01.009.
[3]	Sheng H, Wang Y, Jin Y, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1[J]. Cell Res, 2008, 18(8): 846-857. DOI: 10.1038/cr.2008.80.
[4]	Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection[J]. Nat Immunol, 2007, 8(3): 239-245. DOI: 10.1038/ni1443.
[5]	杨柳, 朱曦龄, 黎功, 等.程序性死亡因子配体1在肝细胞癌中的表达及意义[J].临床肝胆病杂志, 2016, 32(8): 1630-1634. DOI: 10.3969/j.issn.1001-5256.2016.08.047. Yang L, Zhu XL, Li G, et al. Expression of programmed death-ligand 1 in hepatocellular carcinoma and its clinical significance[J]. J Clin Hepatol, 2016, 32(8): 1630-1634. DOI: 10.3969/j.issn.1001-5256.2016.08.047.
[6]	倪勋, 贾永前, 孟文彤, 等.B7-H1在人骨髓间充质干细胞上的表达及其对T淋巴细胞增殖的影响[J].中国实验血液学杂志, 2009, 17(4): 990-993. http://d.wanfangdata.com.cn/Periodical/zgsyxyxzz200904032 Ni X, Jia YQ, Meng WT, et al. Expression of B7-H1 molecule on human bone marrow mesenchymal stem cells and its effects on T lymphocyte proliferation[J]. J Exp Hematol, 2009, 17(4): 990-993. http://d.wanfangdata.com.cn/Periodical/zgsyxyxzz200904032
[7]	Chen Y, Chen S, Liu LY, et al. Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway[J]. Immunol Lett, 2014, 162(2 Pt B): 222-228. DOI: 10.1016/j.imlet.2014.10.021.
[8]	Luz-Crawford P, Noël D, Fernandez X, et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway[J]. PLoS One, 2012, 7(9): e45272. DOI: 10.1371/journal.pone.0045272.
[9]	Wang WB, Yen ML, Liu KJ, et al. Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses[J]. Stem Cell Reports, 2015, 5(3): 392-404. DOI: 10.1016/j.stemcr.2015.07.013.
[10]	Chinnadurai R, Copland IB, Patel SR, et al. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells[J]. J Immunol, 2014, 192(4): 1491-1501. DOI: 10.4049/jimmunol.1301828.
[11]	Yan Z, Zhuansun Y, Chen R, et al. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism[J]. Exp Cell Res, 2014, 324(1): 65-74. DOI: 10.1016/j.yexcr.2014.03.013.
[12]	Yan Z, Zhuansun Y, Liu G, et al. Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions[J]. Immunol Lett, 2014, 162(1 Pt A): 248-255. DOI: 10.1016/j.imlet.2014.09.013.
[13]	Wang H, Qi F, Dai X, et al. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin[J]. Transpl Immunol, 2014, 31(2): 65-74. DOI: 10.1016/j.trim.2014.06.005.
[14]	Gu YZ, Xue Q, Chen YJ, et al. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells[J]. Hum Immunol, 2013, 74(3): 267-276. DOI: 10.1016/j.humimm.2012.12.011.
[15]	Wang G, Zhang S, Wang F, et al. Expression and biological function of programmed death ligands in human placenta mesenchymal stem cells[J]. Cell Biol Int, 2013, 37(2): 137-148. DOI: 10.1002/cbin.10024.
[16]	王国艳, 王斐斐, 李恒, 等.表达PD-L1/PD-L2的人胎盘间充质干细胞对外周血T细胞分泌IL-17的拮抗作用[J].细胞与分子免疫学杂志, 2013, 29(2): 132-136. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=xbfm201302006&dbname=CJFD&dbcode=CJFQ Wang GY, Wang FF, Li H, et al. PD-L1/PD-L2 on human placenta-derived mesenchymal stem cells inhibits the IL-17 secretion of peripheral blood T cells[J]. Chin J Cell Mol Immunol, 2013, 29(2): 132-136. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=xbfm201302006&dbname=CJFD&dbcode=CJFQ
[17]	王炜玮, 李恒, 徐逢皇, 等.γ干扰素上调人胎盘间充质干细胞PD-L1表达并增强其诱导脐血和外周血T细胞向IL-10⁺ T细胞的分化[J].细胞与分子免疫学杂志, 2016, 32(2): 191-195. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=xbfm201602011&dbname=CJFD&dbcode=CJFQ Wang WW, Li H, Xu FH, et al. IFN-gamma up-regulates PD-L1 expression in human placenta mesenchymal stem cells and enhances cell ability to induce the differentiation of IL-10⁺ T cells from cord blood-and peripheral blood-derived T cells[J]. Chin J Cell Mol Immunol, 2016, 32(2): 191-195. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=xbfm201602011&dbname=CJFD&dbcode=CJFQ
[18]	Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO[J]. Immunol Cell Biol, 2010, 88(8): 795-806. DOI: 10.1038/icb.2010.47.
[19]	Jang IK, Yoon HH, Yang MS, et al. B7-H1 inhibits T cell proliferation through MHC class Ⅱ in human mesenchymal stem cells[J]. Transplant Proc, 2014, 46(5): 1638-1641. DOI: 10.1016/j.transproceed.2013.12.059.
[20]	Pan Q, Fouraschen SM, Kaya FS, et al. Mobilization of hepatic mesenchymal stem cells from human liver grafts[J]. Liver Transplant, 2011, 17(5): 596-609. DOI: 10.1002/lt.22260.
[21]	de Mare-Bredemeijer EL, Mancham S, Verstegen MM, et al. Human graft-derived mesenchymal stromal cells potently suppress alloreactive T-cell responses[J]. Stem Cells Dev, 2015, 24(12): 1436-1447. DOI: 10.1089/scd.2014.0485.
[22]	Wu W, Lan Q, Lu H, et al. Human amnion mesenchymal cells negative co-stimulatory molecules PD-L1 expression and its capacity of modulating microglial activation of CNS[J]. Cell Biochem Biophys, 2014, 69(1): 35-45. DOI: 10.1007/s12013-013-9763-9.
[23]	Yoo KH, Jang IK, Lee MW, et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues[J]. Cell Immunol, 2009, 259(2): 150-156. DOI: 10.1016/j.cellimm. 2009.06.010.